[{"id":"29940bae-2e04-4198-8582-ee2667059194","acronym":"","url":"https://clinicaltrials.gov/study/NCT06406465","created_at":"2024-05-11T04:14:20.188Z","updated_at":"2025-02-25T12:30:34.309Z","phase":"Phase 2","brief_title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","source_id_and_acronym":"NCT06406465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-24"},{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"1251a894-93e6-4c49-a11d-e5400df1cba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05605509","created_at":"2022-11-04T16:58:13.524Z","updated_at":"2024-07-02T16:34:26.676Z","phase":"Phase 2","brief_title":"RP-6306 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05605509","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • KRAS • TP53 • CCNE1 • UGT1A1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1","tags":["HER-2 • KRAS • TP53 • CCNE1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (Debio2513)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"0ac2943a-4d67-4442-be19-a4505ba47397","acronym":"NEO-Nal- IRI","url":"https://clinicaltrials.gov/study/NCT03483038","created_at":"2021-01-18T17:09:31.835Z","updated_at":"2024-07-02T16:35:28.824Z","phase":"Phase 2","brief_title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03483038 - NEO-Nal- IRI","lead_sponsor":"University of Florida","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 09/16/2023","primary_completion_date":" 09/16/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-18"},{"id":"588fb289-530f-4478-a18b-c0fb546696df","acronym":"Rapid 1","url":"https://clinicaltrials.gov/study/NCT04786600","created_at":"2021-03-08T12:53:45.858Z","updated_at":"2024-07-02T16:35:28.782Z","phase":"Phase 2","brief_title":"A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial","source_id_and_acronym":"NCT04786600 - Rapid 1","lead_sponsor":"University of Florida","biomarkers":" BRAF • MSI • UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["BRAF • MSI • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-18"},{"id":"ec44533f-4eb5-491d-92bc-8c763456a04b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010888","created_at":"2023-08-25T15:08:21.578Z","updated_at":"2024-07-02T16:35:39.030Z","phase":"Phase 2","brief_title":"Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC","source_id_and_acronym":"NCT06010888","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-08-25"},{"id":"e06060ec-f7b3-4249-8f3e-8a3fa8a80f7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05969899","created_at":"2023-08-01T15:10:04.615Z","updated_at":"2024-07-02T16:35:41.432Z","phase":"Phase 2","brief_title":"Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer","source_id_and_acronym":"NCT05969899","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/10/2024","primary_completion_date":" 07/10/2024","study_txt":" Completion: 02/10/2027","study_completion_date":" 02/10/2027","last_update_posted":"2023-08-01"},{"id":"a673166d-8f54-49d3-b3f6-9abf48fe3d1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05792943","created_at":"2023-03-31T15:02:49.627Z","updated_at":"2024-07-02T16:35:51.687Z","phase":"","brief_title":"UGT1A1 Genotyping in Taiwanese Cancer Patients","source_id_and_acronym":"NCT05792943","lead_sponsor":"National Taiwan University Hospital","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-31"},{"id":"fddf2292-64cd-484d-a9d7-9f0156727a0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02680795","created_at":"2021-09-14T22:55:07.908Z","updated_at":"2024-07-02T16:36:24.432Z","phase":"Phase 1","brief_title":"Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes","source_id_and_acronym":"NCT02680795","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Beleodaq (belinostat)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/27/2016","start_date":" 04/27/2016","primary_txt":" Primary completion: 07/21/2020","primary_completion_date":" 07/21/2020","study_txt":" Completion: 07/21/2020","study_completion_date":" 07/21/2020","last_update_posted":"2021-09-14"},{"id":"f757cf23-54da-48d2-addf-3437d0a05fa8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03443661","created_at":"2021-01-18T16:58:55.900Z","updated_at":"2024-07-02T16:36:35.289Z","phase":"Phase 2","brief_title":"Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT03443661","lead_sponsor":"Aiping Zhou","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/06/2016","start_date":" 02/06/2016","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2021-02-01"},{"id":"86b7520c-3327-4f7a-9e2e-afebe058540a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00628810","created_at":"2021-01-18T02:20:16.601Z","updated_at":"2024-07-02T16:36:38.956Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00628810","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 01/01/2008","primary_completion_date":" 01/01/2008","study_txt":" Completion: 12/01/2008","study_completion_date":" 12/01/2008","last_update_posted":"2020-11-09"},{"id":"4e0ffb47-fabe-4e8b-a9de-300a29ee680f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499586","created_at":"2021-01-18T21:33:20.093Z","updated_at":"2024-07-02T16:36:42.327Z","phase":"Phase 2","brief_title":"A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer","source_id_and_acronym":"NCT04499586","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Tomudex (raltitrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-08-05"},{"id":"5fbaf4b4-f671-4784-8e20-2883ada5d047","acronym":"","url":"https://clinicaltrials.gov/study/NCT04443543","created_at":"2021-01-18T21:23:28.066Z","updated_at":"2024-07-02T16:36:43.754Z","phase":"Phase 2","brief_title":"An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04443543","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 06/22/2020","start_date":" 06/22/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2020-06-30"},{"id":"37bad00e-7cdf-4a79-9496-553a3b6a46e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04411524","created_at":"2021-01-18T21:16:10.310Z","updated_at":"2024-07-02T16:36:44.551Z","phase":"Phase 2","brief_title":"The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04411524","lead_sponsor":"Fudan University","biomarkers":" MSI • UGT1A1","pipe":" | ","alterations":" MSI-H/dMMR • UGT1A1*28 • UGT1A1*1*1","tags":["MSI • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-06-02"},{"id":"5623e6ec-5dda-43ae-a537-eae5c2e8ae4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04411537","created_at":"2021-01-18T21:16:10.567Z","updated_at":"2024-07-02T16:36:44.547Z","phase":"Phase 2","brief_title":"The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04411537","lead_sponsor":"Fudan University","biomarkers":" MSI • UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["MSI • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-06-02"},{"id":"1dcc64d9-6cab-4a9a-834d-237377204d80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04394598","created_at":"2021-01-18T21:12:33.126Z","updated_at":"2024-07-02T16:36:44.935Z","phase":"Phase 2","brief_title":"A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04394598","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-05-19"},{"id":"1f259a16-5526-4fc3-a594-565a553bd51e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00541125","created_at":"2021-01-18T01:58:04.857Z","updated_at":"2024-07-02T16:36:47.262Z","phase":"Phase 2","brief_title":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00541125","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2020-03-30"},{"id":"a73d24b0-4f2d-4d77-8264-32d2f45a53db","acronym":"","url":"https://clinicaltrials.gov/study/NCT04227886","created_at":"2021-01-18T20:34:21.774Z","updated_at":"2024-07-02T16:36:51.346Z","phase":"","brief_title":"Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer","source_id_and_acronym":"NCT04227886","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • irinotecan"],"overall_status":"Unknown status","enrollment":" Enrollment 250","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-01-14"},{"id":"14159743-90fc-4017-8162-710196b3ae6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03116555","created_at":"2021-01-18T15:21:19.556Z","updated_at":"2024-07-02T16:36:53.782Z","phase":"Phase 2","brief_title":"Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA","source_id_and_acronym":"NCT03116555","lead_sponsor":"China Medical University, China","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • irinotecan"],"overall_status":"Unknown status","enrollment":" Enrollment 37","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2019-11-13"},{"id":"a3cf5f39-ca91-443d-bfa1-cb90cf87ae2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00542958","created_at":"2021-01-18T01:58:26.683Z","updated_at":"2024-07-02T16:36:54.219Z","phase":"Phase 1","brief_title":"Study of NK012 in Patients With Refractory Solid Tumors","source_id_and_acronym":"NCT00542958","lead_sponsor":"Nippon Kayaku Co., Ltd.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NK012"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2019-10-28"},{"id":"99455716-76f4-4e4d-bbf9-a549fae663e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00364143","created_at":"2021-01-18T01:15:45.757Z","updated_at":"2024-07-02T16:36:58.355Z","phase":"Phase 1","brief_title":"Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors","source_id_and_acronym":"NCT00364143","lead_sponsor":"Yakult Honsha Co., LTD","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 06/01/2011","study_completion_date":" 06/01/2011","last_update_posted":"2019-07-05"},{"id":"f33c0051-201a-4c80-b788-cbfd33b6c035","acronym":"","url":"https://clinicaltrials.gov/study/NCT01183494","created_at":"2021-01-18T04:43:45.263Z","updated_at":"2024-07-02T16:37:00.344Z","phase":"Phase 1","brief_title":"A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients","source_id_and_acronym":"NCT01183494","lead_sponsor":"University of Chicago","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/12/2009","start_date":" 12/12/2009","primary_txt":" Primary completion: 06/02/2017","primary_completion_date":" 06/02/2017","study_txt":" Completion: 06/02/2017","study_completion_date":" 06/02/2017","last_update_posted":"2019-04-22"},{"id":"35d33ff5-4c4a-4713-9f95-ecc89a575890","acronym":"","url":"https://clinicaltrials.gov/study/NCT03329183","created_at":"2021-01-18T16:26:22.714Z","updated_at":"2024-07-02T16:37:02.767Z","phase":"Phase 2","brief_title":"High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28","source_id_and_acronym":"NCT03329183","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2019-02-15"},{"id":"4fa4cf15-966b-4084-8b10-da1af62ef75b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03824899","created_at":"2021-01-18T18:53:29.981Z","updated_at":"2024-07-02T16:37:03.295Z","phase":"","brief_title":"UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer","source_id_and_acronym":"NCT03824899","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2019-01-31"}]